%D8%A5%D9%86%D8%AF%D9%8A%D9%86%D8%A7%D9%81%D9%8A%D8%B1IndinafirIndinavirIndinavirIndinavirIndinaviiriIndinavirIndinavir%E3%82%A4%E3%83%B3%E3%82%B8%E3%83%8A%E3%83%93%E3%83%ABIndynawir%D8%A7%D9%86%DA%89%D9%8A%D9%86%D8%A7%D9%88%D9%8A%D8%B1IndinavirIndinavirIndinavir%E0%B0%87%E0%B0%82%E0%B0%A1%E0%B0%BF%E0%B0%A8%E0%B0%B5%E0%B0%BF%E0%B0%B0%E0%B1%8D%E0%B8%AD%E0%B8%B4%E0%B8%99%E0%B8%94%E0%B8%B4%E0%B8%99%E0%B8%B2%E0%B9%80%E0%B8%A7%E0%B8%B5%E0%B8%A2%E0%B8%A3%E0%B9%8C%D0%86%D0%BD%D0%B4%D0%B8%D0%BD%D0%B0%D0%B2%D1%96%D1%80IndinavirQ425490
about
sameAs
P3781
Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug IndinavirTreatment With Indinavir and Chemotherapy for Advanced Classical Kaposi's SarcomaIntermittent ART in Primary HIV InfectionExternal-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain MetastasesTrial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple TherapyA Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)A Prospective Cohort of Children With HIV InfectionThe Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving RifampicinStudy to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIVPharmacokinetic Study of Indinavir Drug Levels When Boosted With Ritonavir in ThailandHIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and AmprenavirEvaluation of Therapeutic Drug Monitoring of Protease Inhibitors on Virologic Success and Tolerance of Highly Active Antiretroviral Therapy (HAART)Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug ResistancePaclitaxel in Treating Patients With AIDS-Related Kaposi's SarcomaInteractions Between HIV Protease Inhibitors and Calcium Channel BlockersThe Effect of Milk Thistle on the Pharmacokinetics of IndinavirA Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV InfectionInfluence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy VolunteersUsing Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIVDepo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected WomenRitonavir and Indinavir in Children Failing Other Anti-HIV TreatmentEffectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV InfectionDifferences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV DrugsSafety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV InfectionSafety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing NelfinavirA Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV InfectionDrug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative VolunteersThe Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention TreatmentA Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken IndinavirSafety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV DrugsThe Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV DrugsA Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV DrugsA Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV DrugsA Study of Three Different Anti-HIV Drug Combinations in HIV-Infected PatientsA Study to Compare the Effectiveness of Two Anti-HIV Drug CombinationsA Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and LamivudineA Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include AmprenavirA Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs
P4844
Q61934879-C38B5C54-2301-481C-B48B-C3C150B2AB1BQ61939116-297FEC8F-4B99-4122-AD74-767739B2512EQ64599178-1B6BF12C-702A-41C2-870E-DEDF4E465500Q64721308-673BEAB9-C417-4D93-8C4D-033D97BE1319Q65351095-A5725DF5-8820-4B1E-8CFA-8689116B66A0Q65380156-EB99E663-0DA6-4999-AB61-0B171C074B11Q65382700-9240EB09-881F-4EF6-9D67-9EDA3E64A612Q65385175-66A92966-6B08-4F5B-853F-06F936638073Q65474239-EE203EBD-F884-4CAB-9711-E71ED3A28198Q65545875-0A388642-24D3-4FCB-B065-EEFCE26270A7Q65546536-431E86F9-6396-490C-A15B-70C31A2423D5Q66027834-C55020E6-A322-4CC5-B442-05FE02E8447EQ66029028-A2D3E78B-C687-47DA-947C-048D770080DBQ66032080-50771571-7438-4F7D-8E5C-3AF9EB2F76A2Q66032475-EEF3B324-A6D5-45CA-92EB-0223858C4CF8Q66035602-0865F84A-A232-4314-B21D-E69FE7AB307EQ66038280-3D0BAAA1-3353-41AA-B40F-645AA607DA08Q66038864-47541B09-F8E4-434D-8DC5-76546A50D053Q66039194-F7897DB1-D16D-4773-9E1C-2048414B8355Q66039386-5211A0DE-213D-4068-87AA-EE01E0457143Q66039526-FBD94E54-1B9A-4232-881B-748507BE3116Q66039809-23340B55-8643-4620-8A6C-C3B579B13554Q66039840-09D6C84A-2826-4D0C-AADD-815E3F67D784Q66039913-02A3AB0F-D6C2-46F0-8F26-5023426738A9Q66039925-93C12286-DE15-42F0-808C-67068C34E55DQ66039930-F5DDB502-19DA-4C65-89AA-143D17E66850Q66039934-C5BC483F-3BBE-45D1-A761-40DE75C70282Q66039955-C9F3BB2D-966C-4D0C-8C5C-0B80216946CCQ66039996-D8647DEA-BCA6-40BA-8A76-2CD4504AC0FBQ66040008-30515EDF-3DC4-426F-A3E2-C9064B856170Q66040108-5A42956C-65EC-49D4-95FE-FDAAC340C9A2Q66040109-D614F238-AE69-4A6A-A598-4A43858A3368Q66040117-80D44D78-D7F6-4227-9037-3A8404FDD350Q66040118-388696B2-6590-40A7-AC8B-9CAB235E3039Q66040120-605558B0-BD16-4FC9-A6D8-A5BB7D179D18Q66040124-E7CDE526-09EA-43BF-AF83-254C39C8E1AAQ66040132-D1BD9805-893A-46ED-AA9A-4D8574DD1327Q66040138-3186B6D2-AC55-4978-A4D8-856D6ACD7B4CQ66040140-952B8815-3C4E-41C9-AC6D-2B7A70BC758FQ66040154-A2D388F8-6B38-4F97-9DB2-2F86EC12EE93
P4844
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Indinaviiri
@fi
Indinavir
@de
Indinavir
@es
Indinavir
@id
Indinavir
@nl
Indinavir
@sh
Indinavir
@sl
Indinavir
@sr
Indinavir
@vi
Indynawir
@pl
type
label
Indinaviiri
@fi
Indinavir
@de
Indinavir
@es
Indinavir
@id
Indinavir
@nl
Indinavir
@sh
Indinavir
@sl
Indinavir
@sr
Indinavir
@vi
Indynawir
@pl
altLabel
(1(1S,2R),5(S))-2,3,5-Trideoxy ...... lmethyl)-D-erythro-pentonamide
@cy
(1(1S,2R),5(S))-2,3,5-Trideoxy ...... lmethyl)-D-erythro-pentonamide
@en
Crixivan
@de
Indinavir anhydrous
@cy
Indinavir anhydrous
@en
Indinavir
@en
Indinavirsulfat
@de
L-735524
@cy
L-735524
@en
MK-639
@cy
prefLabel
Indinaviiri
@fi
Indinavir
@de
Indinavir
@es
Indinavir
@id
Indinavir
@nl
Indinavir
@sh
Indinavir
@sl
Indinavir
@sr
Indinavir
@vi
Indynawir
@pl